活血化瘀促進腫瘤血管正常化的機制探討_West China Medical Journal

Authors：

 鐵明慧 ,  張穎

四川大學華西醫院中西醫結合科（成都，610041）;

Corresponding?author：

張穎, Email: 18980602088@189.cn

Keywords：

腫瘤; 活血化瘀; 抗血管治療; 血管正常化

DOI：

10.7507/1002-0179.20140720

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

血瘀證在腫瘤患者中極為常見，活血化瘀法治療腫瘤在臨床上應用廣泛。但活血化瘀藥物抗腫瘤的作用機制尚不明確，對腫瘤血管生成的作用是促進或抑制，一直頗有爭議。從誘導腫瘤血管正常化出發，探討活血化瘀藥物的作用，闡明活血化瘀藥物促進腫瘤血管正常化的機制，以期從根本上闡明活血化瘀藥物治療腫瘤，增加放射治療、化學療法藥物療效的新機制，為活血化瘀藥物用于腫瘤治療提供依據，也為探討更理想有效的中西醫結合綜合治療腫瘤方案提供依據。

Citation： 鐵明慧, 張穎. 活血化瘀促進腫瘤血管正常化的機制探討. West China Medical Journal, 2014, 29(12): 2379-2381. doi: 10.7507/1002-0179.20140720 Copy

1.	李興華, 呂剛, 卜凡儒, 等. 活血化瘀法防治惡性腫瘤研究進展[J]. 中醫臨床研究, 2012, 4(13):113-115.
2.	王文江, 孫玨. 活血化瘀防治惡性腫瘤侵襲轉移研究進展[J]. 江西中醫藥, 2013, 44(7):69-73.
3.	孟華, 朱妙章, 郭軍, 等. 中藥當歸、川芎、丹參提取液促血管生成作用的實驗研究[J]. 中藥材, 2006, 29(6):574-576.
4.	楊運高, 華何與, 陳先明, 等. 中藥抵當湯對小鼠結腸癌脾移植肝轉移模型腫瘤增殖細胞核抗原的影響[J]. 中國老年學雜志, 2013, 33(3):579-581.
5.	吳胤瑛, 李恩孝. VEGF在惡性腫瘤中的研究進展[J]. 現代腫瘤醫學, 2005, 13(5):附18-附21.
6.	高連印, 韋艾凌. 活血化瘀藥調控肝細胞癌微環境細胞因子影響腫瘤轉移復發機制初探[J]. 環球中醫藥, 2014, 7(2):119-121.
7.	王茵萍, 鄒移海, 潘華峰, 等. 活血化瘀防治胃癌的效應與抗新生血管生成的關系[J]. 中國中西醫結合消化雜志, 2005, 13(3):187-189.
8.	Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000, 407(6801):249-257.
9.	Mcdonald DM, Choyke PL. Imaging of angiogenesis:from microscope to clinic[J]. Nat Med, 2003, 9(6):713-725.
10.	Zhao J, Salmon H, Samtinoranont M. Effect of heterogenous vasculature on interstitial transport within a solid tumor[J]. Microvasc Res, 2007, 73(3):224-236.
11.	Fukumura D, Jain RK. Tumor microvasculature and microenvironment:targets for anti-angiogenesis and normalization[J]. Microvasc Res, 2007, 74(2-3):72-84.
12.	Huang G, Chen L. Tumor vasculature and microenvironment normalization:a possible mechanism of antiangiogenesis therapy[J]. Cancer Biother Radiopharm, 2008, 23(5):661-667.
13.	Folkman J. Tumor angiogenesis:therapeutic implications[J]. N Engl J Med, 1971, 285(21):1182-1186.
14.	Steeg PS. Angiogenesis inhibitors:motivators of metastasis?[J]. Nat Med, 2003, 9(7):822-823.
15.	Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation:role of oxygenation, angiopoietin-1, and matrix metalproteinases[J]. Cancer Cell, 2004, 6(6):553-563.
16.	Wong CS, Sceneay J, House CM, et al. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy[J]. Cancer Res, 2012, 72(7):1694-1704.
17.	Shen G, Li Y, Du T, et al. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy[J]. Neoplasma, 2012, 59(5):486-493.
18.	El Kaffas A, Giles A, Czarnota GJ. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound[J]. Angiogenesis, 2013, 16(2):443-454.
19.	Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell, 2009, 15(3):220-231.
20.	Ebos JM, Lee CR, Cruz-Munoz WA, et al. Accelerated metastasis after Short-Term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell, 2009, 15(3):232-239.
21.	Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy[J]. Nat Rev Cancer, 2008, 8(8):592-603.
22.	Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab:pooled analysis of randomized phase Ⅲ trials[J]. J Clin Oncol, 2011, 29(1):83-88.
23.	Padera TP, Kuo AH, Hoshida T, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib[J]. Mol Cancer Ther, 2008, 7(8):2272-2279.
24.	Jain RK. Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J]. Science, 2005, 307(576):58-62.
25.	Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases[J]. Nat Rev Drug Discov, 2011, 10(6):417-427.
26.	Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases[J]. Physiol Rev, 2011, 91(3):1071-1121.
27.	Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J]. Cancer Sci, 2011, 102(7):1253-1256.
28.	王秀麗, 周亞興, 李海燕. 活血化瘀對血管內皮功能的影響[J]. 中國醫院用藥評價與分析, 2010, 10(10):956-957.
29.	周曾同, 金芝貴, 張水龍, 等. 燈盞細辛對金地鼠頰囊癌血管生成影響的形態特征研究[J]. 臨床口腔醫學雜志, 2000, 16(3):166-169.
30.	陳緒元, 朱宇熹, 陳曉品, 等. 平消膠囊與放療同步治療中晚期鼻咽癌增敏研究[J]. 臨床腫瘤學雜志, 2005, 10(2):163-165.
31.	耿長新, 曾昭沖, 王吉耀. 多烯紫杉醇在體內對肝癌的抑制和放射增敏作用[J]. 中華肝臟病雜志, 2005, 13(1):60-61.
32.	喬新梅, 趙金嶺. 血府逐瘀湯聯合化療治療瘀阻肺絡證小細胞肺癌40例療效觀察[J]. 新中醫, 2013, 4(2):55-56.

1. 李興華, 呂剛, 卜凡儒, 等. 活血化瘀法防治惡性腫瘤研究進展[J]. 中醫臨床研究, 2012, 4(13):113-115.
2. 王文江, 孫玨. 活血化瘀防治惡性腫瘤侵襲轉移研究進展[J]. 江西中醫藥, 2013, 44(7):69-73.
3. 孟華, 朱妙章, 郭軍, 等. 中藥當歸、川芎、丹參提取液促血管生成作用的實驗研究[J]. 中藥材, 2006, 29(6):574-576.
4. 楊運高, 華何與, 陳先明, 等. 中藥抵當湯對小鼠結腸癌脾移植肝轉移模型腫瘤增殖細胞核抗原的影響[J]. 中國老年學雜志, 2013, 33(3):579-581.
5. 吳胤瑛, 李恩孝. VEGF在惡性腫瘤中的研究進展[J]. 現代腫瘤醫學, 2005, 13(5):附18-附21.
6. 高連印, 韋艾凌. 活血化瘀藥調控肝細胞癌微環境細胞因子影響腫瘤轉移復發機制初探[J]. 環球中醫藥, 2014, 7(2):119-121.
7. 王茵萍, 鄒移海, 潘華峰, 等. 活血化瘀防治胃癌的效應與抗新生血管生成的關系[J]. 中國中西醫結合消化雜志, 2005, 13(3):187-189.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000, 407(6801):249-257.
9. Mcdonald DM, Choyke PL. Imaging of angiogenesis:from microscope to clinic[J]. Nat Med, 2003, 9(6):713-725.
10. Zhao J, Salmon H, Samtinoranont M. Effect of heterogenous vasculature on interstitial transport within a solid tumor[J]. Microvasc Res, 2007, 73(3):224-236.
11. Fukumura D, Jain RK. Tumor microvasculature and microenvironment:targets for anti-angiogenesis and normalization[J]. Microvasc Res, 2007, 74(2-3):72-84.
12. Huang G, Chen L. Tumor vasculature and microenvironment normalization:a possible mechanism of antiangiogenesis therapy[J]. Cancer Biother Radiopharm, 2008, 23(5):661-667.
13. Folkman J. Tumor angiogenesis:therapeutic implications[J]. N Engl J Med, 1971, 285(21):1182-1186.
14. Steeg PS. Angiogenesis inhibitors:motivators of metastasis?[J]. Nat Med, 2003, 9(7):822-823.
15. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation:role of oxygenation, angiopoietin-1, and matrix metalproteinases[J]. Cancer Cell, 2004, 6(6):553-563.
16. Wong CS, Sceneay J, House CM, et al. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy[J]. Cancer Res, 2012, 72(7):1694-1704.
17. Shen G, Li Y, Du T, et al. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy[J]. Neoplasma, 2012, 59(5):486-493.
18. El Kaffas A, Giles A, Czarnota GJ. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound[J]. Angiogenesis, 2013, 16(2):443-454.
19. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell, 2009, 15(3):220-231.
20. Ebos JM, Lee CR, Cruz-Munoz WA, et al. Accelerated metastasis after Short-Term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell, 2009, 15(3):232-239.
21. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy[J]. Nat Rev Cancer, 2008, 8(8):592-603.
22. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab:pooled analysis of randomized phase Ⅲ trials[J]. J Clin Oncol, 2011, 29(1):83-88.
23. Padera TP, Kuo AH, Hoshida T, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib[J]. Mol Cancer Ther, 2008, 7(8):2272-2279.
24. Jain RK. Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J]. Science, 2005, 307(576):58-62.
25. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases[J]. Nat Rev Drug Discov, 2011, 10(6):417-427.
26. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases[J]. Physiol Rev, 2011, 91(3):1071-1121.
27. Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J]. Cancer Sci, 2011, 102(7):1253-1256.
28. 王秀麗, 周亞興, 李海燕. 活血化瘀對血管內皮功能的影響[J]. 中國醫院用藥評價與分析, 2010, 10(10):956-957.
29. 周曾同, 金芝貴, 張水龍, 等. 燈盞細辛對金地鼠頰囊癌血管生成影響的形態特征研究[J]. 臨床口腔醫學雜志, 2000, 16(3):166-169.
30. 陳緒元, 朱宇熹, 陳曉品, 等. 平消膠囊與放療同步治療中晚期鼻咽癌增敏研究[J]. 臨床腫瘤學雜志, 2005, 10(2):163-165.
31. 耿長新, 曾昭沖, 王吉耀. 多烯紫杉醇在體內對肝癌的抑制和放射增敏作用[J]. 中華肝臟病雜志, 2005, 13(1):60-61.
32. 喬新梅, 趙金嶺. 血府逐瘀湯聯合化療治療瘀阻肺絡證小細胞肺癌40例療效觀察[J]. 新中醫, 2013, 4(2):55-56.

Previous Article
推進醫院非在編職工加入工會工作的探討
Next Article
CYP2C19基因多態性與個體化治療的研究進展

West China Medical Journal

活血化瘀促進腫瘤血管正常化的機制探討

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content